10.09.2023, 1236 Zeichen

Valneva: Specialty vaccine company Valneva and Pfizer announced positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, when given as a booster. These results from the VLA15-221 Phase 2 study showed a strong anamnestic antibody response for all serotypes in pediatric (5 to 11 years of age) and adolescent participants (12 to 17 years of age), as well as in adults (18 to 65 years of age), one month after administration of a booster dose (month 19). “Protection against Lyme disease is important for anyone who lives or spends time outdoors in areas where Lyme disease is endemic. This data from the VLA15-221 study is vital to improve our understanding of how vaccination may help to protect both adults and children from this potentially devastating disease,” said Annaliesa Anderson, Senior Vice President and Head Vaccine Research and Development at Pfizer. “We are encouraged by the positive Phase 2 results for VLA15, and, in partnership with Valneva, look forward to continuing to study the vaccine candidate in ongoing Phase 3 clinical trials.”
Valneva: weekly performance: -1.30%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (07/09/2023)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #816: Erste Group x5, Bohemian BKS und wie unser wikifolio-Alert für Österreich funktioniert

Bildnachweis

Aktien auf dem Radar:Austriacard Holdings AG, Addiko Bank, Agrana, Pierer Mobility, CA Immo, Verbund, EVN, AT&S, BKS Bank Stamm, Kostad, Marinomed Biotech, Wolford, Cleen Energy, Polytec Group, Warimpex, Stadlauer Malzfabrik AG, Kapsch TrafficCom, UBM, Zumtobel, RHI Magnesita, Flughafen Wien, Oberbank AG Stamm, FACC, Palfinger, Amag, Immofinanz, OMV, Österreichische Post, Rosenbauer, Telekom Austria, Uniqa.

---